FDA approved the use of solanta cream in the treatment of rosacea

Source: MedSci 2014-12-29 the U.S Food and drug administration has approved 1% ivermectin cream (soolantra, Galderma laboratory), once a day for the treatment of inflammatory lesions, rosacea pimples, acne Rosacea is a common chronic skin disease that is estimated to affect 16 million Americans, mostly women, over the age of 30 Specific causes are facial redness, pimples, unknown rosacea pimples, but studies have shown multiple triggers, including exposure to the sun, alcohol, spicy food, and exercise Recent evidence also suggests that rosacea may be caused by excessive proliferation of skin mites The company said the active ingredient of ivermectin cream has anti-inflammatory and anti parasitical activities The oily base is staffy moisturizer, and the formulas recommended by dermatologists are fragrance free, mild and non irritating The approval of ivermectin cream was based on a randomized, 12 week, three-stage, double-blind, blank controlled trial of 910 rosacea patients In both studies, ivermectin cream reached its primary treatment success end point once a day, defined by investigators with a clear global assessment rating for changes in skin and inflammatory lesion counts The company said that the observation of the first two weeks is beneficial to the continuous improvement of the efficacy Rosacea "is a challenge to conditions and often varies from patient to patient and usually requires a customized approach," said Linda Stein, MD, consultant at the third phase of clinical research at galerma "Although some treatment conditions such as acne rosacea and erythematous acne may take more than 4 weeks to show the effect, Soolantra cream can provide preliminary results as early as two weeks ago." In a 12 week extended study, ivermectin cream was safe, although some side effects such as skin burns and skin allergies were reported, but good tolerance increased by 40 weeks (52 weeks in total).